Advice
Following a full submission
Exemestane (Aromasin) is accepted for restricted use within NHS Scotland for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2–3 years of initial adjuvant tamoxifen therapy.
Exemestane has shown benefit in terms of disease-free survival when given as an alternative to tamoxifen after initial adjuvant treatment with tamoxifen for 2-3 years. It offers an alternative to tamoxifen after initial adjuvant treatment with tamoxifen for 2-3 years and has a different adverse effects profile.
Treatment with Exemestane is restricted to initiation by a breast cancer specialist.
Download detailed advice47KB (PDF)
Medicine details
- Medicine name:
- Exemestane 25mg tablets (Aromasin®)
- SMC ID:
- 210/05
- Indication:
- Postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2 - 3 years of initial adjuvant tamoxifen therapy
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 07 November 2005